Mandate

Vinge has advised CELLINK in connection with directed issues of SEK 3 billion

Vinge has advised CELLINK AB (publ) in connection with a directed issue of covertibles of SEK 1.5 billion and a directed issue of B-shares of SEK 1.5 billion, in total SEK 3 billion.

The convertibles and the shares have been offered by way of an accelerated bookbuilding process arranged by Citigroup Global Markets, J.P. Morgan and Carnegie Investment Bank. The convertibles and shares were subscribed for by Swedish and international institutional investors.

Vinge’s team has consisted of Anders Strid, Edin Agic, Hampus Olsson, Linus Adolfsson and Maria Schultzberg (tax). Sullivan & Cromwell has advised Cellink in relation to English and US laws.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026